Answer
Ramucirumab (Cyramza) with erlotinib is indicated as first-line treatment for adults with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.
Sources for this answer
- Cyramza 10 mg/ml concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.1 Therapeutic Indications · Version 18Document updated
Sources checked